Log In
Print
BCIQ
Print
Print this Print this
 

T-VEC, talimogene laherparepvec (formerly OncoVEX GM-CSF)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionModified herpes simplex virus type 1 (HSV-1) carrying the gene for GM-CSF
Molecular Target
Mechanism of ActionOncolytic virus
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentRegistration
Standard IndicationMelanoma
Indication DetailsTreat melanoma; Treat metastatic melanoma
Regulatory Designation U.S. - Special Protocol Assessment (Treat metastatic melanoma);
U.S. - Standard Review (Treat metastatic melanoma);
EU - Standard Review (Treat metastatic melanoma)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$1,000.0M

$425.0M

$575.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today